|

17th Virtual Thoracic Oncology Spring Symposium

{{ getTitle(live) }}

{{ toDate(live.liveStartDate) }}

{{ toTime(live.liveStartDate) }} - {{ toTime(live.liveEndDate) }}


{{ getNotification(live) }}

Programme

 

Session 1: 

Healthcare policy

chair persons: Jan van Meerbeeck & Veerle Surmont

European Cancer Organisations’ Essential Requirements for Quality Lung Cancer Care

Yolande Lievens, UZ Ghent, Belgium

The Dutch Lung Cancer Audit: lessons learnt

Hans Smit, Arnhem, the Netherlands

 

Session 2:

Radiotherapy

chair persons: Charlotte Billiet & Yolande Lievens

Hippocampal avoidance during PCI: a multicenter international randomised trial

José Belderbos, Amsterdam, the Netherlands

Is watchful waiting a valid alternative for PCI in SCLC?

Corinne Faivre-Finn, Manchester, United Kingdom

 

Session 3: 

Systemic disease and treatment

chair persons: Annelies Janssens & Karim Vermaelen

Resistance after immunotherapy?

Laurent Greillier, Marseille, France

pro/con DEBATE – adjuvant osimertinib

PRO: Lizza Hendriks,  Maastricht,  the Netherlands

CON: Jacques Cadranel, Paris, France

TERAVOLT: results of an international survey on the impact of COVID-19 in patients with thoracic cancer

Marina Garassino, Chicago, US

 

Closure

 

 

 

 

 

 

 

 

Programme

 

Session 1: 

Healthcare policy

chair persons: Jan van Meerbeeck & Veerle Surmont

European Cancer Organisations’ Essential Requirements for Quality Lung Cancer Care

Yolande Lievens, UZ Ghent, Belgium

The Dutch Lung Cancer Audit: lessons learnt

Hans Smit, Arnhem, the Netherlands

 

Session 2:

Radiotherapy

chair persons: Charlotte Billiet & Yolande Lievens

Hippocampal avoidance during PCI: a multicenter international randomised trial

José Belderbos, Amsterdam, the Netherlands

Is watchful waiting a valid alternative for PCI in SCLC?

Corinne Faivre-Finn, Manchester, United Kingdom

 

Session 3: 

Systemic disease and treatment

chair persons: Annelies Janssens & Karim Vermaelen

Resistance after immunotherapy?

Laurent Greillier, Marseille, France

pro/con DEBATE – adjuvant osimertinib

PRO: Lizza Hendriks,  Maastricht,  the Netherlands

CON: Jacques Cadranel, Paris, France

TERAVOLT: results of an international survey on the impact of COVID-19 in patients with thoracic cancer

Marina Garassino, Chicago, US

 

Closure